| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Pi-Methylimidazoleacetic acid hydrochloride targets histamine metabolism pathways and acts as an endogenous metabolite. It is involved in histamine catabolism, mast cell activity, and allergic or inflammatory responses. The compound's potential neurotoxic properties suggest interactions with neurological signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, Pi-Methylimidazoleacetic acid hydrochloride is used in biochemical studies to investigate histamine metabolism and immune modulation. The compound's effects on mast cell activity and histamine catabolism are studied in cell-based systems. Its potential neurotoxic properties are evaluated in neuronal cell models.
|
| ln Vivo |
In vivo activity data for Pi-Methylimidazoleacetic acid hydrochloride are limited. As a potential neurotoxin and metabolite, it may affect neurological function and immune responses in animal models. However, direct pharmacological effects of the compound itself are not extensively characterized.
|
| Enzyme Assay |
In vitro enzyme assays for Pi-Methylimidazoleacetic acid hydrochloride typically involve studying its role in histamine metabolism. The compound is used in assays measuring histamine N-methyltransferase or diamine oxidase activity. Enzyme activity is assessed by monitoring the conversion of histamine to its metabolites using HPLC or spectrophotometric methods.
|
| Cell Assay |
Cellular assays for Pi-Methylimidazoleacetic acid hydrochloride are conducted using mast cells, immune cells, or neuronal cell lines. Cells are treated with the compound at concentrations ranging from 1-100 uM for 6-24 hours. Histamine release is measured by ELISA. Mast cell activation is assessed by measuring degranulation and cytokine production. Neurotoxicity is evaluated by assessing cell viability (MTT assay), oxidative stress markers, and neuronal morphology.
|
| Animal Protocol |
In vivo animal studies for Pi-Methylimidazoleacetic acid hydrochloride are not well-established. As a research compound, it may be used in models of histamine-related disorders or neurotoxicity. Standard protocols would involve administration via intraperitoneal or oral routes with assessment of neurological function, immune responses, and histamine levels.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Pi-Methylimidazoleacetic acid hydrochloride are limited. As a small molecule, it is expected to have moderate bioavailability and distribution. The compound is soluble in DMSO and other organic solvents. Storage conditions are powder at -20degC for 3 years. No specific PK parameters have been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for Pi-Methylimidazoleacetic acid hydrochloride indicate that it is a potential neurotoxin. This classification suggests that the compound may have adverse effects on the nervous system at certain concentrations. Standard safety precautions should be followed when handling the compound. It is for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
Pi-Methylimidazoleacetic acid hydrochloride is a research-use compound not approved for clinical therapeutic applications. It is used in biomedical research to investigate pathways linked to histamine catabolism, mast cell activity, and allergic or inflammatory responses. The compound is also valuable for studying the role of imidazole derivatives in neurological signaling and the mechanisms of neurotoxicity.
|
| Molecular Formula |
C6H9CLN2O2
|
|---|---|
| Molecular Weight |
176.600860357285
|
| Exact Mass |
176.035
|
| CAS # |
1071661-55-6
|
| Related CAS # |
Pi-Methylimidazoleacetic acid;4200-48-0
|
| PubChem CID |
69892609
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
138
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.OC(CC1=CN=CN1C)=O
|
| InChi Key |
BMKRZGIAUKYDQE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H8N2O2.ClH/c1-8-4-7-3-5(8)2-6(9)10;/h3-4H,2H2,1H3,(H,9,10);1H
|
| Chemical Name |
2-(3-methylimidazol-4-yl)acetic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~707.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (11.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (11.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (11.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6625 mL | 28.3126 mL | 56.6251 mL | |
| 5 mM | 1.1325 mL | 5.6625 mL | 11.3250 mL | |
| 10 mM | 0.5663 mL | 2.8313 mL | 5.6625 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
